Nabriva Therapeutics plc - NBRV STOCK NEWS

Nabriva Therapeutics (NASDAQ: NBRV) announced the granting of non-statutory stock options for 106,000 ordinary shares to two newly hired employees, including 100,000 shares to Daniel Dolan, the new CFO. The options have an exercise price of $1.66 per share, matching the closing price on the grant date of March 31, 2021. Each option has a 10-year term and vests over four years, contingent on continued employment. This action is part of Nabriva's compensation strategy under Nasdaq rules, aiming to incentivize talent acquisition.

Nabriva Therapeutics (NASDAQ: NBRV) announced that CEO Ted Schroeder will present a company overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 2:15 p.m. ET. Interested parties can access the presentation via the 'Investors' section on Nabriva's website. Nabriva is focused on developing innovative anti-infective treatments like XENLETA® for community-acquired bacterial pneumonia and CONTEPO™ for complicated urinary tract infections. The company has a partnership with Merck to market SIVEXTRO® in the U.S.

Nabriva Therapeutics announces positive results from a post-hoc analysis published in The Journal of Emergency Medicine. The data from the LEAP 2 Phase 3 trial shows that moderate to severe community-acquired bacterial pneumonia (CABP) can be effectively treated as outpatients with a 5-day oral regimen of XENLETA, a novel antibiotic. Success rates for XENLETA were comparable to moxifloxacin, with 91% for early clinical response. This trial emphasizes the economic and clinical benefits of outpatient treatment, particularly for patients with advanced age or comorbidities.

Nabriva Therapeutics (NBRV) reported Q4 2020 revenues of $2.5 million, a $2.2 million increase year-over-year, mainly from collaboration revenues. However, full-year revenues decreased by $4.5 million to $5.0 million, attributed to reduced collaboration and product revenues. The company successfully raised $23.4 million through a recent financing. Nabriva relaunches XENLETA and SIVEXTRO in the community with 60 sales representatives and plans a Phase 1 clinical trial for XENLETA in cystic fibrosis patients. As of December 31, 2020, cash reserves stood at $41.4 million.

Nabriva Therapeutics (NASDAQ: NBRV) will report its Q4 and full-year 2020 financial results on March 11, 2021, after U.S. market close. Management will host a conference call at 4:30 p.m. ET to discuss these results and recent company highlights. Nabriva is focused on anti-infective agents, with FDA approval for XENLETA® for community-acquired bacterial pneumonia and developing CONTEPO™ for complicated urinary tract infections. Interest will be on financial performance and commercial potential of its products.

Nabriva Therapeutics (NASDAQ: NBRV) announced a registered direct offering to healthcare-focused investors, selling approximately 10.36 million ordinary shares and warrants to purchase up to 5.18 million additional shares. The combined purchase price is $2.4525 per ordinary share and warrant. The gross proceeds from this offering are expected to be around $25.4 million, closing on or about March 3, 2021. H.C. Wainwright & Co. is the exclusive placement agent for this offering, which aims to support the company’s operations in developing anti-infective agents.

Nabriva Therapeutics (NASDAQ: NBRV) announced the appointment of Daniel Dolan as Chief Financial Officer (CFO), effective March 12, 2021, succeeding Gary Sender, who will transition to a consulting role. Dolan brings over 20 years of biopharmaceutical finance experience, previously serving at Radius Health and Shire Pharmaceuticals. Nabriva's CEO, Ted Schroeder, expressed confidence in Dolan's expertise to drive financial discipline and top-line growth, aiming to enhance shareholder value. The company is focused on developing innovative anti-infective treatments.

Nabriva Therapeutics announced a study revealing a 39.5% overall macrolide resistance in S. pneumoniae across the U.S., with rates exceeding 25% in most regions. The research highlighted higher resistance in outpatients (45.3%) compared to inpatients (37.8%). These findings indicate a pressing need for new treatment options for community-acquired bacterial pneumonia (CABP), as macrolide use is declining due to rising resistance.

Macrolide-resistant S. pneumoniae poses a significant public health threat, necessitating innovative treatments like Nabriva's XENLETA.

Nabriva Therapeutics (NASDAQ: NBRV) announced the retirement of CFO Gary Sender effective March 12, 2021. Sender will continue as a consultant to ensure a smooth transition. CEO Ted Schroeder praised Sender's contributions during his tenure, highlighting his role in Nabriva's transformation into a commercial organization. Nabriva is focused on developing anti-infective agents, with FDA approval for XENLETA and ongoing development of CONTEPO, while also maintaining exclusive marketing rights for SIVEXTRO.